KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Assets (2018 - 2025)

Historic Assets for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $562.8 million.

  • Castle Biosciences' Assets rose 937.12% to $562.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $562.8 million, marking a year-over-year increase of 937.12%. This contributed to the annual value of $531.2 million for FY2024, which is 1718.25% up from last year.
  • Latest data reveals that Castle Biosciences reported Assets of $562.8 million as of Q3 2025, which was up 937.12% from $544.7 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Assets ranged from a high of $562.8 million in Q3 2025 and a low of $425.4 million during Q2 2023
  • Moreover, its 5-year median value for Assets was $457.8 million (2022), whereas its average is $469.5 million.
  • As far as peak fluctuations go, Castle Biosciences' Assets surged by 26366.45% in 2021, and later tumbled by 719.49% in 2023.
  • Castle Biosciences' Assets (Quarter) stood at $462.6 million in 2021, then fell by 3.3% to $447.3 million in 2022, then increased by 1.34% to $453.3 million in 2023, then rose by 17.18% to $531.2 million in 2024, then grew by 5.94% to $562.8 million in 2025.
  • Its Assets was $562.8 million in Q3 2025, compared to $544.7 million in Q2 2025 and $501.7 million in Q1 2025.